M

Molecure SA
WSE:MOC

Watchlist Manager
Molecure SA
WSE:MOC
Watchlist
Price: 9.1 PLN -1.09% Market Closed
Market Cap: 183.8m PLN

EV/EBIT
Enterprise Value to EBIT

-5.5
Current
-13.8
Median
15.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-5.5
=
Enterprise Value
136.4m PLN
/
EBIT
-24.9m PLN
Market Cap EV/EBIT
PL
Molecure SA
WSE:MOC
183.8m PLN -5.5
US
Eli Lilly and Co
NYSE:LLY
779.4B USD 47.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
394B USD 17.2
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 15.6
CH
Roche Holding AG
SIX:ROG
236.5B CHF 13.6
UK
AstraZeneca PLC
LSE:AZN
177B GBP 193.8
US
Merck & Co Inc
NYSE:MRK
225.9B USD 10.5
CH
Novartis AG
SIX:NOVN
199.7B CHF 14.7
IE
Endo International PLC
LSE:0Y5F
167.6B USD 670.8
US
Pfizer Inc
NYSE:PFE
142.8B USD 12.1
EBIT Growth EV/EBIT to Growth
PL
M
Molecure SA
WSE:MOC
Average EV/EBIT: 1 869.8
Negative Multiple: -5.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.2
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
16%
1
CH
Roche Holding AG
SIX:ROG
13.6
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
193.8
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.5
12%
0.9
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.1
10%
1.2

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-4.5
2-Years Forward
EV/EBIT
-10.2
3-Years Forward
EV/EBIT
-3